Product Description
For Parkinson's Disease (PD)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Texas Health Science Center, Houston
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Parkinson's Disease|Hepatitis A|Clostridium Infections|Hepatitis, Alcoholic|Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Colitis, Ulcerative|Fatty Liver, Alcoholic|Inflammation|Scleroderma, Systemic|Scleroderma, General|Constipation|Scleroderma, Diffuse
Phase 1: Parkinson's Disease|Colitis, Ulcerative|HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PRIM-DJ2727 | N/A |
Available |
Clostridium Infections|Pneumonia|Urinary Tract Infections|Klebsiella Infections|Communicable Diseases |
None |
2021-01-25 |
||
| HSC-MS-23-0016 | P1 |
Recruiting |
Colitis, Ulcerative |
2026-12-15 |
2024-05-11 |
||
| HSC-SPH-18-0621 | P1 |
Completed |
Parkinson's Disease |
2022-10-09 |
2023-05-25 |
||
| HSC-MS-17-0782 | P1 |
Completed |
HIV Infections |
2019-10-08 |
2019-12-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| HSC-MS-24-0630 | P2 |
Recruiting |
Scleroderma, Diffuse|Constipation|Scleroderma, Systemic|Scleroderma, General |
2026-05-30 |
2025-06-27 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| HSC-MS-20-0316 | P2 |
Recruiting |
Colitis, Ulcerative|Inflammation |
2025-12-31 |
2024-02-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| H-43752 | P2 |
Recruiting |
Hepatitis A|Hepatitis, Alcoholic |
2025-06-30 |
2025-01-24 |
||
| HSC-SPH-19-1126 | P2 |
Withdrawn |
Non-alcoholic Fatty Liver Disease|Fatty Liver, Alcoholic|Liver Diseases, Alcoholic |
2024-12-01 |
2024-05-15 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
| FMT | P2 |
Withdrawn |
Clostridium Infections |
2022-01-30 |
2021-01-29 |
Primary Endpoints|Treatments |
|
| UT-SPH/KRF FMT-2016-PD-01 | P2 |
Withdrawn |
Parkinson's Disease |
2018-07-17 |
2019-03-21 |
Treatments |